1. Home
  2. EPIX vs FORA Comparison

EPIX vs FORA Comparison

Compare EPIX & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EPIX
  • FORA
  • Stock Information
  • Founded
  • EPIX 2009
  • FORA 2014
  • Country
  • EPIX Canada
  • FORA United States
  • Employees
  • EPIX N/A
  • FORA N/A
  • Industry
  • EPIX Biotechnology: Pharmaceutical Preparations
  • FORA Computer Software: Prepackaged Software
  • Sector
  • EPIX Health Care
  • FORA Technology
  • Exchange
  • EPIX Nasdaq
  • FORA Nasdaq
  • Market Cap
  • EPIX 75.9M
  • FORA 66.1M
  • IPO Year
  • EPIX N/A
  • FORA N/A
  • Fundamental
  • Price
  • EPIX $1.87
  • FORA $1.93
  • Analyst Decision
  • EPIX Hold
  • FORA Strong Buy
  • Analyst Count
  • EPIX 3
  • FORA 1
  • Target Price
  • EPIX $2.00
  • FORA $5.00
  • AVG Volume (30 Days)
  • EPIX 452.3K
  • FORA 13.4K
  • Earning Date
  • EPIX 08-04-2025
  • FORA 08-13-2025
  • Dividend Yield
  • EPIX N/A
  • FORA N/A
  • EPS Growth
  • EPIX N/A
  • FORA N/A
  • EPS
  • EPIX N/A
  • FORA N/A
  • Revenue
  • EPIX N/A
  • FORA $22,332,001.00
  • Revenue This Year
  • EPIX N/A
  • FORA $46.25
  • Revenue Next Year
  • EPIX N/A
  • FORA $11.30
  • P/E Ratio
  • EPIX N/A
  • FORA N/A
  • Revenue Growth
  • EPIX N/A
  • FORA 5.22
  • 52 Week Low
  • EPIX $1.40
  • FORA $1.85
  • 52 Week High
  • EPIX $7.88
  • FORA $4.03
  • Technical
  • Relative Strength Index (RSI)
  • EPIX 63.77
  • FORA 43.48
  • Support Level
  • EPIX $1.86
  • FORA $1.92
  • Resistance Level
  • EPIX $1.88
  • FORA $2.06
  • Average True Range (ATR)
  • EPIX 0.02
  • FORA 0.08
  • MACD
  • EPIX 0.00
  • FORA -0.01
  • Stochastic Oscillator
  • EPIX 94.74
  • FORA 7.41

About EPIX ESSA Pharma Inc.

ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.

About FORA Forian Inc.

Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.

Share on Social Networks: